📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

COVID-19: Live Updates for Wednesday, May 6 

Published 06/05/2020, 12:46 pm
Updated 06/05/2020, 12:48 pm
© Shutterstock
GILD
-

Rolling updates on the latest developments and headlines from around the world on the Covid-19 pandemic.

By Gina Lee and Peter Nurse

(10:40 PM ET) The White House mulls disbanding Presidential COVID-19 task force

Vice President Mike Pence said the White House is discussing whether to disband the president’s COVID-19 task force, possibly as soon as May 25.

The move comes as Pence said that the task force accomplished its goal of containing the virus as the outbreak in the U.S. slows and some states reopen after weeks-long lockdowns.

(10:37 PM ET) Gilead to Expand Remdesivir Production

Gilead Sciences (NASDAQ:GILD) is looking to expand manufacturing of its Covid-19 treatment remdesivir. The drug received FDA emergency use approval earlier in the week.

Gilead said in a blog post that it is talking with “some of the world’s leading chemical and pharmaceutical manufacturing companies” about their ability to make the drug for Europe, Asia and the developing world through 2022.

It is also in talks with Indian and Pakistani manufacturers about manufacturing and licensing he drug for developing markets.

(10:34 PM ET) Argentina to get $4 billion Development Bank of Latin America loan

Argentina secured a $4 billion loan from the Development Bank of Latin America, with the funds to be used to tackle the economic impact of the virus. 

DBLA will distribute the funds over four years. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.